The development of an antiviral vaccine or therapeutic drug against COVID-19 begins with matching a chemical concept with the potential prophylactic mechanism of the future vaccine or future antiviral activity in vivo.
Utengenezaji wa chanjo au dawa ya kingavirusi ya COVID 19 huanza kwa kulinganisha dhana ya kemikali na mbinu inayowezekana ya kinga ya chanjo za baadaye au shughuli za kingavirusi katika vivo.